Insider Transactions Reported by 22 Insiders of Climb Bio, Inc.

Symbol: CLYM on Nasdaq
Location: Wellesley Hills, MA

Quick Takeaways

CLYM - Climb Bio, Inc. has 22 insiders with reported activity on this page.
Net insider value flow over the last year: -$126,450.
Recent transaction rows are available for direct filing-level review.

What Changed

Buy value: $779,626; sell value: $906,075.
Net share flow: +149,812.

Why This Matters

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Source Evidence

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Net insider flow leans to selling over the last 12 months. Net value: -$126,450.

Buys

$779,626

Shares: 321,672

Insiders: 1

Sells

$906,076

Shares: 171,860

Insiders: 3

Net

-$126,450

Shares: +149,812

Insiders: -2

Window (months)	Buy shares	Sell shares	Buy $	Sell $	Net $
0-3	0	150,000	$0	$879,382	-$879,382
3-6	321,672	0	$779,626	$0	+$779,626
6-9	0	0	$0	$0	$0
9-12	0	21,860	$0	$26,694	-$26,694

Climb Bio, Inc. executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Valuation	Report Date
AI ETI LLC	10%+ Owner	$62,617,500			Filing P/S	12 Aug 2021
RA CAPITAL MANAGEMENT, L.P.	Director, 10%+ Owner	$11,912,001	+$779,626	+7%	Filing P/S	05 Jan 2026
Aoife Brennan	President and CEO, Director	$2,042,709	-$25,154	-1.2%	Mixed	06 Jan 2026
Stephen Basil Thomas	Director	$1,116,399	-$879,382	-44%	Mixed	25 Feb 2026
Brett Kaplan	Chief Operating Officer	$618,450			Mixed	13 Jan 2025
Valerie Morisset	Evp, R&D And Cso	$249,910			Filing P/S	19 Jul 2024
Emily Pimblett	SVP, Finance & CAO	$63,821	-$1,540	-2.4%	Mixed	18 Jun 2025
Susan Altschuller	Chief Financial Officer				Mixed	06 Jan 2026
Perrin Megan Wilson	Chief Business Officer				Mixed	06 Jan 2026
Douglas E. Williams	Director				Mixed	04 Jun 2025
Kimberlee C. Drapkin	Director				Mixed	04 Jun 2025
Judith Dunn	Director				Mixed	04 Jun 2025
Andrew David Levin	Director				Mixed	04 Jun 2025
Cindy Driscoll	Senior Vice President, Finance				Mixed	06 Jan 2026
Alexander Cumbo	Director				Mixed	04 Jun 2025
Leone D. Patterson	Director				Mixed	19 May 2022
Robert Azelby	President & CEO, Director				Mixed	31 Oct 2022
Liam Ratcliffe	Director				Mixed	26 Jun 2024
James B. Bucher	EVP and General Counsel				Mixed	31 Oct 2022
Simon Tate	Director				Mixed	26 Jun 2024
Adam Joseph Rosenberg	Director				Mixed	26 Jun 2024
Erin Lavelle	Coo & Cfo				Mixed	31 Oct 2022

Top shareholders of Climb Bio, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
RA CAPITAL MANAGEMENT, L.P.	13F 13D/G 3/4/5	Company · Director, 10%+ Owner	33% from 13D/G	11,293,828	$77,711,233	—	31 Dec 2025	13F 13D/G 3/4/5
AI ETI LLC	3/4/5	10%+ Owner	— class O/S missing	5,009,400	$62,617,500	—	12 Aug 2021	3/4/5
MPM BioImpact LLC	13D/G 13F	Company	5.6%	2,671,480	$13,437,544	$0	31 Dec 2025	13D/G 13F
Pontifax Management 4 G.P. (2015) Ltd.	13D/G	Pontifax VI G.P. L.P.	7.7%	5,206,380	$12,911,822	$0	27 Jun 2024	13D/G
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	4%	1,923,639	$7,695,000	—	31 Dec 2025	13F
ADAR1 Capital Management, LLC	13F	Company	3%	1,432,475	$5,729,900	—	31 Dec 2025	13F
VANGUARD GROUP INC	13F	Company	2.8%	1,340,504	$5,362,016	—	31 Dec 2025	13F
Affinity Asset Advisors, LLC	13F	Company	2.7%	1,300,000	$5,200,000	—	31 Dec 2025	13F
Kynam Capital Management, LP	13F	Company	2.2%	1,028,341	$4,113,364	—	31 Dec 2025	13F
GREAT POINT PARTNERS LLC	13F	Company	2.1%	979,534	$3,918,136	—	31 Dec 2025	13F
SPHERA FUNDS MANAGEMENT LTD.	13F	Company	2%	932,247	$3,728,988	—	31 Dec 2025	13F
Point72 Asset Management, L.P.	13F	Company	1.5%	716,680	$2,866,720	—	31 Dec 2025	13F
DRIEHAUS CAPITAL MANAGEMENT LLC	13F	Company	1.3%	600,946	$2,403,784	—	31 Dec 2025	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	1.2%	566,712	$2,266,848	—	31 Dec 2025	13F
Peapod Lane Capital LLC	13F	Company	1.2%	565,992	$2,263,968	—	31 Dec 2025	13F
Aoife Brennan	3/4/5	President and CEO, Director	— mixed-class rows	954,382 mixed-class rows	$2,042,709	-$25,154	06 Jan 2026	3/4/5
NAN FUNG TRINITY (HK) Ltd	13F	Company	0.97%	463,654	$1,854,616	—	31 Dec 2025	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.93%	445,342	$1,781,368	—	31 Dec 2025	13F
Kevin Kotler	13F	Individual	0.84%	400,000	$1,600,000	—	31 Dec 2025	13F
BlackRock, Inc.	13F	Company	0.82%	389,309	$1,557,236	—	31 Dec 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.67%	320,600	$1,282,400	—	31 Dec 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.65%	310,756	$1,243,615	—	31 Dec 2025	13F
MARSHALL WACE, LLP	13F	Company	0.64%	304,015	$1,216,060	—	31 Dec 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.62%	296,314	$1,185,256	—	31 Dec 2025	13F
Stephen Basil Thomas	3/4/5	Director	— mixed-class rows	194,657 mixed-class rows	$1,116,399	-$879,382	25 Feb 2026	3/4/5
TD ASSET MANAGEMENT INC	13F	Company	0.52%	246,200	$984,800	—	31 Dec 2025	13F
CITADEL ADVISORS LLC	13F	Company	0.5%	239,043	$956,172	—	31 Dec 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.47%	224,883	$899,532	—	31 Dec 2025	13F
683 Capital Management, LLC	13F	Company	0.42%	201,652	$806,608	—	31 Dec 2025	13F
JANE STREET GROUP, LLC	13F	Company	0.39%	187,403	$749,612	—	31 Dec 2025	13F
BRIDGEWAY CAPITAL MANAGEMENT, LLC	13F	Company	0.33%	159,300	$637,200	—	31 Dec 2025	13F
Brett Kaplan	3/4/5	Chief Operating Officer	— mixed-class rows	577,500 mixed-class rows	$618,450	—	13 Jan 2025	3/4/5
MORGAN STANLEY	13F	Company	0.31%	148,538	$594,152	—	31 Dec 2025	13F
MANUFACTURERS LIFE INSURANCE COMPANY, THE	13F	Company	0.29%	140,617	$566,650	—	31 Dec 2025	13F
AMERIPRISE FINANCIAL INC	13F	Company	0.29%	139,529	$558,116	—	31 Dec 2025	13F
STATE STREET CORP	13F	Company	0.27%	128,900	$515,600	—	31 Dec 2025	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.26%	124,700	$498,800	—	31 Dec 2025	13F
NORTHERN TRUST CORP	13F	Company	0.26%	124,670	$498,680	—	31 Dec 2025	13F
ArchPoint Investors	13F	Company	0.25%	121,400	$485,600	—	31 Dec 2025	13F
Squadron Capital Management LLC	13F	Company	0.21%	100,000	$400,000	—	31 Dec 2025	13F
OMERS ADMINISTRATION Corp	13F	Company	0.18%	85,466	$341,864	—	31 Dec 2025	13F
Seven Fleet Capital Management LP	13F	Company	0.16%	76,400	$305,600	—	31 Dec 2025	13F
UBS Group AG	13F	Company	0.15%	71,323	$285,292	—	31 Dec 2025	13F
Valerie Morisset	3/4/5	EVP, R&D AND CSO	— mixed-class rows	41,515 mixed-class rows	$249,910	—	19 Jul 2024	3/4/5
LPL Financial LLC	13F	Company	0.13%	62,000	$248,000	—	31 Dec 2025	13F
BARCLAYS PLC	13F	Company	0.13%	61,853	$247,412	—	31 Dec 2025	13F
Hudson Bay Capital Management LP	13F	Company	0.1%	48,736	$194,944	—	31 Dec 2025	13F
XTX Topco Ltd	13F	Company	0.07%	34,852	$139,408	—	31 Dec 2025	13F
Qube Research & Technologies Ltd	13F	Company	0.07%	34,596	$138,384	—	31 Dec 2025	13F
CITIZENS FINANCIAL GROUP INC/RI	13F	Company	0.06%	28,168	$112,672	—	31 Dec 2025	13F

Recent Insider Transactions by Companies or Individuals for Climb Bio, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership
Stephen Basil Thomas	CLYM	Common Stock	Sale	-9.54%	$114,289	$7.01	-16,313	154,657	26 Feb 2026	Direct
Stephen Basil Thomas	CLYM	Common Stock	Sale	-16.5%	$235,964	$7.00	-33,687	170,970	25 Feb 2026	Direct
Stephen Basil Thomas	CLYM	Common Stock	Sale	-4.66%	$58,141	$5.81	-10,000	204,657	13 Feb 2026	Direct
Stephen Basil Thomas	CLYM	Common Stock	Sale	-29.5%	$470,988	$5.23	-90,000	214,657	12 Feb 2026	Direct
Aoife Brennan	CLYM	Stock Option (Right to Buy)	Award				700,000	700,000	06 Jan 2026	Direct
Perrin Megan Wilson	CLYM	Stock Option (Right to Buy)	Award				300,000	300,000	06 Jan 2026	Direct
Susan Altschuller	CLYM	Stock Option (Right to Buy)	Award				142,500	142,500	06 Jan 2026	Direct
Cindy Driscoll	CLYM	Stock Option (Right to Buy)	Award				100,000	100,000	06 Jan 2026	Direct
Ra Capital Management, L.P.	CLYM	Common Stock	Purchase	0.21%	$24,888	$3.50	7,111	3,403,429	05 Jan 2026	See footnotes
Ra Capital Management, L.P.	CLYM	Common Stock	Purchase	3.08%	$290,181	$2.86	101,462	3,396,318	12 Dec 2025	See footnotes
Ra Capital Management, L.P.	CLYM	Common Stock	Purchase	6.91%	$464,556	$2.18	213,099	3,294,856	11 Dec 2025	See footnotes
Ra Capital Management, L.P.	CLYM	Common Stock	Disposed to Issuer	-86.9%			-20,440,000	3,081,757	11 Dec 2025	See footnotes
Ra Capital Management, L.P.	CLYM	Pre-Funded Warrants (Right to Buy)	Award				20,440,000	20,440,000	11 Dec 2025	See footnotes
Susan Altschuller	CLYM	Stock Option (Right to Buy)	Award				600,000	600,000	01 Oct 2025	Direct
Stephen Basil Thomas	CLYM	Common Stock	Award	49.1%			100,375	304,657	07 Aug 2025	Direct
Aoife Brennan	CLYM	Common Stock	Sale	-30%	$25,154	$1.22	-20,618	48,132	30 Jun 2025	Direct
Aoife Brennan	CLYM	Common Stock	Options Exercise				68,750	68,750	27 Jun 2025	Direct
Aoife Brennan	CLYM	Restricted Stock Units	Options Exercise	-25%			-68,750	206,250	27 Jun 2025	Direct
Stephen Basil Thomas	CLYM	Common Stock	Options Exercise	14%			25,094	204,282	27 Jun 2025	Direct
Stephen Basil Thomas	CLYM	Restricted Stock Units	Options Exercise	-100%			-25,094	0	27 Jun 2025	Direct
Emily Pimblett	CLYM	Common Stock	Sale	-6.17%	$1,540	$1.24	-1,242	18,888	20 Jun 2025	Direct
Emily Pimblett	CLYM	Common Stock	Options Exercise	33%			5,000	20,130	18 Jun 2025	Direct
Emily Pimblett	CLYM	Restricted Stock Units	Options Exercise	-25%			-5,000	15,000	18 Jun 2025	Direct
Cindy Driscoll	CLYM	Stock Option (Right to Buy)	Award				200,000	200,000	17 Jun 2025	Direct
Ra Capital Management, L.P.	CLYM	Stock Option (Right to Buy)	Award				40,000	40,000	04 Jun 2025	See Footnotes
Kimberlee C. Drapkin	CLYM	Stock Option (Right to Buy)	Award				40,000	40,000	04 Jun 2025	Direct
Alexander Cumbo	CLYM	Stock Option (Right to Buy)	Award				40,000	40,000	04 Jun 2025	Direct
Judith Dunn	CLYM	Stock Option (Right to Buy)	Award				40,000	40,000	04 Jun 2025	Direct
Douglas E. Williams	CLYM	Stock Option (Right to Buy)	Award				40,000	40,000	04 Jun 2025	Direct
Andrew David Levin	CLYM	Stock Option (Right to Buy)	Award				40,000	40,000	04 Jun 2025	Direct
Stephen Basil Thomas	CLYM	Stock Option (Right to Buy)	Award				40,000	40,000	04 Jun 2025	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.